The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in patients with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable disease (SD) for at least 12 weeks, assessed according to RECIST 1.1 criteria).